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ABSTRACT
Objective: to analyse the association between rectal bleeding
or a family history of colorectal cancer (CRC) and the results ob-
tained in two rounds of a CRC screening pilot programme per-
formed in L’Hospitalet, Barcelona, Spain.
Subjects: males and females (50-69 years) were the target
population. Together with the invitation letter, they received a
questionnaire in which they were asked about rectal bleeding,
family history of CRC and related neoplasms. The screening test
was a guaiac-based faecal occult blood test (FOBT), and
colonoscopy for positive tests.
Results: 25,829 FOBT were performed in 18,405 individu-
als. Information on rectal bleeding and a family history of CRC
were obtained for 9,849 and 9,865 cases, respectively. Male sex
(OR = 1.32), 60-69 years of age (OR = 1.48), rectal bleeding (OR
= 1.84) and history of CRC (OR = 1.54) were independent pre-
dictors of positive FOBT. With regard to colonoscopy, a greater
risk of diagnosing advanced neoplasm was observed among men
(OR = 2.47) and subjects with a family history of CRC (OR =
1.98).
Conclusions: CRC screening programmes must have instru-
ments that make it possible to select the candidate population and
the possibility of offering a study suited to the risk of individuals
who are not susceptible to population screening by means of
FOBT.
Key words: Colorectal cancer screening. Fecal occult blood test.
Rectal bleeding. Family history of CRC. Risk assessment.
INTRODUCTION
Early diagnosis in colorectal cancer (CRC) remains cru-
cial to the outcome of surgery, which is the cornerstone op-
tion for cure. The incidence and mortality of CRC in the
European Union is considered so disturbing that the Euro-
pean Union Commissioner on Health has recommended
screening programmes with faecal occult blood test
(FOBT) to be considered in all member states (1).
Population screening programmes target individuals
above 50 years old without additional risk factors (symp-
toms suggestive of the existence of CRC, chronic inflam-
matory disease, personal history of adenomas, CRC or
family risk of CRC) (2-4). Clinical guidelines exist for
screening high-risk patients, including those with a histo-
ry of familial polyposis or hereditary non-polyposis col-
orectal cancer (5,6). The possibility of investigating
whether the individuals to be screened have additional
risk factors constitutes an added difficulty in the context
of screening programmes on large populations due to the
significant cost entailed by carrying out exhaustive med-
ical histories in participating subjects who may be sus-
pected to belong to higher-risk groups.
We present the prospective results of the questionnaire
included in the first two rounds performed in a pilot CRC
screening programme based on FOBT performed in
L'Hospitalet, Barcelona. The study endpoint is to evalu-
ate the efficacy of this questionnaire by analysing screen-
ing results and the presence of rectal bleeding or family
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history of colorectal cancer in the participating popula-
tion in the two rounds performed.
METHODS
The CRC pilot screening programme was directed at
the 50-to-69-year-old population in L’Hospitalet, a city of
239,000 inhabitants in the metropolitan area of Barcelona
(Catalonia), Spain. Demographic data on this population
was gathered from the Primary Healthcare Information
System. A hospital cancer registry covering the city was
linked to exclude subjects with a diagnosis of colorectal
cancer. Two screening rounds were successively per-
formed. The first round involved 11,011 of the 63,880
people invited to participate. The second round involved
14,818 of the 66,534 people invited (7).
The population regarded as subject to screening were
sent a letter inviting them to participate in the pro-
gramme, including information on the prevention of CRC
and a questionnaire in which they were asked about any
episodes of rectal bleeding, previous diagnosis of haem-
orrhoids, adenomas, colorectal cancer or inflammatory
bowel disease, having had a colonoscopy in the previous
5 years, as well as the existence of a family member with
CRC or other neoplasms associated with CRC (endome-
trial and kidney). The questionnaire was sent to the whole
target population in the first round, and to the new sub-
jects invited to take part in the second round. Since in
some cases the participants returned the questionnaire
unanswered, the requested information is not available
for all of them.
All subjects with CRC, adenomas or chronic inflam-
matory bowel disease were definitely excluded from the
screening program. Subjects with a previous colonoscop-
ic examination were considered candidates for screening
after 5 years of colonoscopy.
When the questionnaire reported two or more relatives
with cancer, they were phoned through the programme to
check the information and evaluate whether the subject
was eligible for population screening with FOBT or met
the criteria for hereditary colorectal cancer (5,6). If a high
risk family history was confirmed, the subject was ex-
cluded from the programme and was offered to be coun-
selled for a more detailed assessment. The programme al-
lowed the screening of subjects with a family history of
CRC or other non-colonic neoplasms as long as they did
not meet the criteria for hereditary cancer. Rectal bleed-
ing was not considered an exclusion criterion.
The screening test was a guaiac-based faecal occult
blood test every 2 years. Participants were asked to collect
two stool samples from three bowel movements. Dietary
restriction was indicated when a repetition of the test was
necessary. If 5 or 6 samples were positive at initial testing,
or any of the samples under dietary restriction, a
colonoscopy with sedation was indicated. Any polyps
found were removed and biopsies of any masses were ob-
tained. If a patient had more than 1 polyp, the most ad-
vanced pathologic lesion was included in the analysis. The
histological classification of polyps and cancers was based
on World Health Organisation criteria (8). High-risk ade-
noma (HRA) was defined as adenoma with severe dyspla-
sia, adenoma bigger than 10 mm, more than 2 adenomas,
or any adenoma with tubulovillous or villous histology.
Carcinoma in situ was classified as HRA. Low-risk adeno-
ma (LRA) was defined as that of smaller size, tubular type
and low-grade dysplasia. Advanced neoplasms included
invasive cancer or high-risk adenoma.
In the analysis we have taken into account only one
FOBT result for each individual. Hence in participants of
both rounds with a positive FOBT in the second round
we used the results of the questionnaire sent in the first
round.
Differences in categorical variables were compared
with the Chi-square test. In the multivariate analysis, the
association between a positive FOBT or an advanced
neoplasm with the presence of rectal bleeding or a family
history of colorectal cancer was analysed using logistic
regression, adjusting by sex and age. The variables in-
cluded in the multivariate analysis were sex, age and
those with a significant result in the bivariate analysis.
The results were expressed as odds ratios (OR) with 95%
confidence intervals (95%CI). Differences were consid-
ered statistically significant when p < 0.05. All analyses
were performed with the Stata software, version 9.2
(StataCorp, College Station, TX, USA) and SPSS soft-
ware (version 13.0 for Windows).
RESULTS
A total of 1,691 individuals were excluded (986 from
the first round and 705 from the second round), 592
(35.0%) of whom were excluded by means of the assess-
ment of risk factors included in the questionnaires and
considered not eligible for population screening: 262
CRCs, 33 inflammatory bowel diseases, 44 previously
diagnosed colon adenomas, 243 had undergone colono-
scopies in the previous 5 years, and 10 subjects were ex-
cluded due to meeting the criteria for hereditary CRC.
Table I describes the data of participants in both
rounds. A total of 25,829 FOBTs were performed in
18,405 individuals, 7,424 of whom participated in both
rounds. The results of the study have recently been
analysed (7,9). The uptake of colonoscopy among sub-
jects with a positive test was 89% (442/495).
Colonoscopy results were: without findings in 229 sub-
jects, 36 invasive cancers, 121 HRA (33.1% of whom had
an in situ carcinoma), 29 LRA and 27 non-neoplastic
polyps. Of the 18,405 people screened, 14,740 question-
naires were received with some of the requested data.
From these, information was obtained on the presence of
blood in faeces and a family history of CRC in 9,849 and
in 9,865 cases, respectively.
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Table II analyses these two factors in greater detail. It
can be observed that rectal bleeding was more frequent in
participants with a positive result in FOBT (41.8%), in
men (31.7%), in the 50 to 59 age group (30.6%), and in
those presenting haemorrhoids (43.2%). The cases that
most frequently reported the presence of rectal bleeding
were those diagnosed with an invasive cancer (64.3%);
42.9% of individuals without neoplasms (cancer or adeno-
mas) on colonoscopy had haemorrhoids. It can also be ob-
served in table II that the presence of a family history was
more frequent among positive FOBTs (11.0%), in men
(7.6%), and in the 50 to 59-year age group (7.8%). People
with high-risk adenoma detected followed by invasive
cancer were those with the highest frequency of family his-
tories of CRC with 15.9 and 13.9%, respectively.
In the bivariate analysis, the positive result of FOBT
was statistically significant with the variables studied ex-
cept for the presence of haemorrhoids (Table III). Signifi-
cance was maintained in the multivariate model for each
one of the variables, so that a positive FOBT was related
to the male gender (OR = 1.32, 95% CI, 1.08-1.62), be-
longing to the 60 to 69-year age group (OR = 1.48, 95%
CI, 1.21-1.81), the presence of rectal bleeding (OR =
1.84, 95% CI, 1.50-2.26), and having a family history of
CRC (OR = 1.54, 95%CI, 1.11-2.14).
Table IV presents the results of the analysis of the as-
sociation between the diagnosis of advanced neoplasm
and the presence of rectal bleeding or family history of
CRC. In the bivariate analysis, the diagnosis of advanced
neoplasm was significantly associated with the male gen-
der and the presence of a family history. No association
was found with the presence of rectal bleeding or haem-
orrhoids. In the multivariate model, it was observed that
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Table I. Results of the first and second rounds
n %
People screened 18,405
Sex
Female 10,016 54.4
Male 8,389 45.6
Age group (years)
50-59 10,201 55.4
60-69 8,204 44.6
FOBT results
Positive 495 2.7
Negative 17,304 94.0
Not assessable 606 3.3
Colonoscopies 442 89.3
Colonoscopy result
Normal 229 51.8
Invasive cancer 36 8.1
High risk adenoma 121 27.4
Low risk adenoma 29 6.6
Non-neoplastic polyp 27 6.1
Questionnaires 14,740 80.1
Rectal bleeding
No 6,997 47.5
Yes 2,852 19.3
Unanswered 4,891 33.2
Family history of CRC
No 9,134 62.0
Yes 731 4.9
Unanswered 4,875 33.1
Haemorrhoids
No 4,780 32.4
Yes 5,249 35.6
Unanswered 4,711 32.0
Tabla II. Characteristics of people with rectal bleeding or family history of CRC who answered the questionnaire
Rectal bleeding Family history of CRC
No Yes No Yes
n % n % p-value n % n % p-value
FOBT result
Positive 234 58.2 168 41.8 < 0.001 372 89.0 46 11.0 < 0.005
Negative 6,763 71.6 2,684 28.4 8,762 92.7 685 7.3
Sex
Female 3,851 73.5 1,392 26.5 < 0.001 4,863 92.7 381 7.3 0.585
Male 3,146 68.3 1,460 31.7 4,271 92.4 350 7.6
Age group (years)
50-59 3,877 69.4 1,705 30.6 < 0.001 5,152 92.2 440 7.8 0.051
60-69 3,120 73.1 1,147 26.9 3,982 93.2 291 6.8
Screening-detected lesions
Invasive cancer 10 35.7 18 64.3 0.016 31 86.1 5 13.9 0.669
High risk adenoma1 61 62.9 36 37.1 90 84.1 17 15.9
Low risk adenoma 21 80.8 5 19.2 22 88.0 3 12.0
Non-neoplasic polyp 14 58.3 10 41.7 21 91.3 2 8.7
Without lesions 108 57.1 81 42.9 174 92.1 15 7.9
Haemorrhoids
No 4,058 86.5 631 13.5 < 0.001 4,344 92.6 345 7.4 0.952
Yes 2,923 56.8 2,220 43.2 4,761 92.6 381 7.4
1Carcinomas in situ are included.
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the risk of presenting an advanced neoplasm was greater
among men (OR = 2.47, 95% CI, 1.59-3.83) and among
people with a family history of CRC (OR = 1.98, 95%
CI, 1.02-3.84).
DISCUSSION
Our findings from the two first rounds of the Colorec-
tal Cancer Screening Programme show the higher risk of
a diagnosis of advanced colorectal neoplasm among male
participants (OR = 2.47, 95% CI, 1.59-3.83) and in those
with a family history of CRC (OR = 1.98, 95% CI, 1.02-
3.84). The results according to age group and presence of
rectal bleeding were not significant.
Currently, there are published guidelines on the differ-
ent strategies of CRC screening according to the risk in
the population (5,10). An annual or biennial FOBT is cur-
rently recommended for people above 50 with average
risk. Ameta-analysis has suggested that the magnitude of
the relative reduction in mortality rate by FOBT screen-
ing is 16% overall and 23% after adjustment for screen-
ing attendance (11).
Few data have examined the prevalence of inappropriate
CRC screening (12,13). Fisher et al. (13) investigated a
sample of 500 consecutive patients who had a FOBT. Over-
all, 35% of patients received inappropriate screening, 20%
because of signs or symptoms of gastrointestinal blood loss
or a higher-than-average risk of CRC. If we take into ac-
count the progressive increase in the screening of the low-
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Table III. Analysis of positive FOBT
Bivariate analysis Multivariate analysis
n (%) OR (95% CI) p-value OR (95% CI) p-value
Sex
Men 272 (54.9) 1.47 (1.22-1.77) < 0.001 1.32 (1.08-1.62) < 0.001
Women 223 (45.1) 1 1
Age (years)
60-69 243 (49.1) 1.61 (1.35-1.95) < 0.001 1.48 (1.21-1.81) < 0.001
50-59 252 (50.9) 1 1
Rectal bleeding
Yes 168 (41.8) 1.81 (1.47-2.23) < 0.001 1.84 (1.50-2.26) < 0.001
No 234 (58.2) 1 1
Family history of CRC
Yes 46 (11.0) 1.58 (1.14-2.19) 0.0041 1.54 (1.11-2.14) < 0.001
No 372 (89.0) 1 1
Haemorrhoids
Yes 219 (55.2) 0.92 (0.75-1.12) 0.443 – –
No 178 (44.8) 1
Table IV. Analysis of participants in which screening detected an advanced neoplasm
Bivariate analysis Multivariate analysis
n (%) OR (95% CI) p-value OR (95% CI) p-value
Sex
Men 106 (67.5) 2.41(1.57-3.70) < 0.001 2.47(1.59-3.83) < 0.001
Women 51 (32.5) 1 1
Age (years)
60-69 79 (50.3) 1.14 (0.85-1.40) 0.5062 1.10 (0.72-1.69) 0.650
50-59 78 (49.7) 1 1
Rectal bleeding
Yes 54 (43.2) 1.13 (0.71-1.80) 0.5767 – –
No 71 (56.8) 1
Family history of CRC
Yes 22 (15.4) 1.97 (0.99-3.94) 0.0366 1.98 (1.02-3.84) 0.043
No 121 (84.6) 1 1
Haemorrhoids
Yes 58 (50.4) 1.34 (0.86-2.10) 0.211 – –
No 57 (49.6) 1
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risk population, it is important to apply the quality mea-
sures required to guarantee that the screening is performed
in individuals with eligibility criteria. The questionnaires
may provide sufficient information to make it possible to
detect individuals at higher risk, even although this entails
an increase in difficulty and cost when dealing with screen-
ing programmes for large populations.
One of the important points to be investigated is if
some symptoms may suggest the presence of CRC and
because of that a diagnosis procedure should be indicated
instead of a population screening. However, it is difficult
to diagnose CRC because symptoms may be diffuse
(3,14), and associated gastrointestinal distress is frequent
in the general population (15,16). Rectal bleeding is a
nonspecific symptom and may be due to different condi-
tions, most of them benign, such as haemorrhoids or anal
fissures (the most frequent), and also malignant, such as
colorectal cancer. Although 40% of patients with CRC
report rectal blood loss, the risk of CRC in a patient with
rectal bleeding is low (17-19). On assessing the symp-
toms, gender and age differences in risk of CRC must be
taken into account. In the study of Lawrenson and associ-
ates (16) men with symptoms were more likely to be di-
agnosed with CRC than women.
There are few published studies that investigate the pres-
ence of symptoms in the population subjected to screening.
Although rectal bleeding is a predictive symptom of col-
orectal cancer in the population with screening sigmoi-
doscopy, a majority of cancers and adenomas in this group
were detected in individuals who were asymptomatic (20).
Ahmed et al. (21) demonstrated, in a CRC screening pilot
study, that lower gastrointestinal symptoms are common
among individuals who have a positive FOBT. However,
symptoms were not related to colonoscopy findings. In our
study, approximately 42% of patients with no findings at
colonoscopy or with non-neoplastic polyps reported rectal
bleeding. According to the authors, possible explanations
for the high prevalence of symptoms may include that these
patients respond to screening more than those actually
asymptomatic, or else that intestinal symptoms are frequent
in the general population. Our data, in agreement with the
literature, show that rectal bleeding was present in 43.2% of
those diagnosed with an advanced neoplasm, was more fre-
quent in men than in women, and in people aged between
50 and 59 years more than among those between 60 and 69
years. However, rectal bleeding was not associated with a
higher risk of advanced neoplasm (OR = 1.13, 95% CI,
0.71-1.80). As reported by Ahmed et al. (21), the presence
of rectal bleeding alone, as investigated in our screening
programme questionnaire, without taking into account the
actual characteristics of this or whether there were other
symptoms present, may increase the sensitivity of the test
without significantly predicting the diagnosis of advanced
neoplasm.
Individuals with a family history of CRC have a high
risk of developing the disease (5), which increases when
it is associated with early age of onset or multiple affect-
ed relatives (22-24). Colonoscopy surveillance has been
shown to reduce the incidence and mortality of colorectal
cancer, not only in families with a history of hereditary
nonpolyposis colorectal cancer (HNPCC) (5,23) but also
in individuals with a moderate risk due to a family histo-
ry but not fulfilling any of the Amsterdam or Bethesda
criteria (23-25). In families at moderate risk, it is recom-
mended that colonoscopy surveillance be initiated at the
age of 45-50 years, since the likelihood of detecting an
advanced neoplasm in people under the age of 45 is very
small (23,24,26-28). In our study, the presence of a fami-
ly history of CRC without HNPCC criteria is associated
both with a positive result of FOBT and a diagnosis of
advanced neoplasm.
Although our results are similar to others already pub-
lished in the literature (21-24,28), they must be assessed
within the context of a prospective study of a question-
naire with some limitations. In the first place, as the ques-
tionnaires were only sent once to participants in both
rounds, it was implicitly assumed that the responses
would be the same after two years. Secondly, no other
symptoms other than rectal bleeding were considered. In
the third place, the questionnaire investigated the exis-
tence of relatives with three types of cancer, allowing the
screening of individuals with family history without tak-
ing into account that the risk of CRC varies according to
age at diagnosis, type of relative, and number of relatives
affected. These data suggest that the characteristics of our
questionnaire probably allowed the screening of individ-
uals with a greater risk of developing colorectal disease.
In fact, and as a result of the findings of this study, we
have modified the questionnaire to be sent to the candi-
date individuals in coming rounds. In addition to rectal
bleeding, the presence of other symptoms in the previous
3-6 months will be evaluated, such as changes in bowel
habit, abdominal pain and anaemia due to iron depletion.
In terms of family history, the number, age and the degree
of relationship of family members with CRC will be in-
vestigated. Depending on the response, we will exclude
non-candidates from the screening programme and refer
them to more specific measures.
The complexity involved in the development of
screening programmes in CRC in large populations com-
pels us to ascertain all the factors into which the popula-
tion may be grouped for different types of screening or
age of onset according to the risk of developing the dis-
ease. Among these factors, mention may be made of the
higher incidence of CRC in males and at an earlier age
(29), and the greater risk in the presence of a history of
CRC in first-degree relatives (27,28,30). These results
may therefore have important implications for the offer
of CRC screening programmes and their optimisation in
terms of cost effectiveness (31).
In summary, CRC population screening programmes
should be offered to eligible individuals using appropri-
ate instruments that make it possible to adapt the type of
screening to the risk of individuals to be screened. The
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questionnaires must be easy to interpret by the population
and the data that may constitute grounds for exclusion
collected. Moreover, the questionnaires should be read by
trained personnel and, in cases of exclusion due to symp-
toms or family history of CRC, there should be the possi-
bility of specific screening. The introduction of people
with a higher risk, besides offering an unsuitable test for
these population groups, could alter the results expected
in this type of screening.
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